Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NIH Awards $7.8 Million for Innovative HIV Vaccine Approaches

Published: Wednesday, August 22, 2012
Last Updated: Wednesday, August 22, 2012
Bookmark and Share
The grants were awarded under the Innovation for HIV Vaccine Discovery initiative, which is expected to receive up to $34.8 million over the next four years.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded 14 grants totaling $7.8 million in first-year funding for basic research to identify new approaches for designing a safe and effective HIV vaccine.

"Recent discoveries about the basic biology of HIV and how the virus adapts to its host have provided useful information and new opportunities to guide vaccine development," said NIAID Director Anthony S. Fauci, M.D. "These grants are designed to build on that information and stimulate discovery of new ways to design a robust vaccine that prevents acquisition and establishment of latent infection."

The 14 HIV Vaccine Discovery (IHVD) grant recipient organizations include:

Altravax Inc. (Sunnyvale, Calif.)

• Principal Investigator: Robert Whalen, DSc.
• Project title: Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-1.
• The initial award, supported by grant number 1R01AI10270601, is for $597,816 for fiscal year 2012.

Catholic University of America (Washington, D.C.)
• Principal Investigator: Venigalla Rao, Ph.D.
• Project title: Potent Phage T4-Derived V2 Immunogens as HIV Vaccines.
• The initial award, supported by grant number 1R01AI10272501, is for $413,787 for fiscal year 2012.

Dartmouth College (Hanover, N.H.)
• Principal Investigator: Margaret Ackerman, Ph.D.
• Project title: Applying High-Performance Protein Engineering Tools to HIV Immunogen Design.
• The initial award, supported by grant number 1R01AI10269101, is for $479,437 for fiscal year 2012.
Duke University (Durham, N.C.)
• Principal Investigator: Herman Staats, Ph.D.
• Project title: Mucosal Vaccination to Protect Against HIV-1 Infection at Mucosal Sites.
• The initial award, supported by grant number 1R01AI10274701, is for $492,072 for fiscal year 2012.
Harvard Medical School (Boston)
• Principal Investigator: Amitinder Kaur, M.D.
• Project title: Natural Killer T Cells as Modulators of AIDS Vaccine Efficacy.
• The initial award, supported by grant number 1R01AI10269301, is for $846,896 for fiscal year 2012.
Massachusetts General Hospital (Boston)
• Principal Investigator: Galit Alter, Ph.D.
• Project title: Tuning Fc-Effector Functions of HIV-Specific Antibodies.
• The initial award, supported by grant number 1R01AI10266001, is for $609,875 for fiscal year 2012.
NYU Langone Medical Center (New York City)
• Principal Investigator: Catarina Hioe, Ph.D.
• Project title: Contributions of Anti-V2 Antibodies in Protection Against HIV.
• The initial award, supported by grant number 1R01AI10274001, is for $579,543 for fiscal year 2012.
University of California (Irvine)
• Principal Investigator: Donald Forthal, M.D.
• Project title: The Impact of Antibody and pH on Female-to-Male SIV Infection.
• The initial award, supported by grant number 1R01AI10271501, is for $718,324 for fiscal year 2012.
University of Maryland (Baltimore)
• Principal Investigator: Charles Pauza, Ph.D.
• Project title: Neonatal Fc-Receptor-Targeted Mucosal HIV Vaccine.
• The initial award, supported by grant number 1R01AI10268001, is for $779,175 for fiscal year 2012.
University of Medicine and Dentistry of New Jersey (Newark)
• Principal Investigator: Abraham Pinter, Ph.D.
• Project title: Optimizing Protective Vaccine Targets in the V1/V2 Domain of HIV-1 gp120.
• The initial award, supported by grant number 1R01AI10271801, is for $566,739 for fiscal year 2012.
University of Minnesota (Minneapolis)
• Principal Investigator: Ashley Haase, M.D.
• Project title: Vaccine Design to Concentrate Protective Antibodies at the Mucosal Border.
• The initial award, supported by grant number 1R01AI10262501, is for $843,856 for fiscal year 2012.
University of North Carolina (Chapel Hill)
• Principal Investigator: Nikolay Dokholyan, Ph.D.
• Project title: Immunogen Design to Target Carbohydrate-Occluded Epitopes on the HIV envelope.
• The initial award, supported by grant number 1R01AI10273201, is for $514,331 for fiscal year 2012.
University of Rochester (Rochester, N.Y.)
• Principal Investigator: Mark Dumont, Ph.D.
• Project title: Yeast Genetic Approach to Enhance the Immunogenicity of HIV Envelope Glycoprotein.
• The initial award, supported by grant number 1R01AI10273001, is for $386,250 for fiscal year 2012.
University of Texas at El Paso
• Principal Investigator: June Kan-Mitchell, Ph.D.
• Project title: Effector and Regulatory Activities of HLA-E-restricted HIV-specific CD8 T Cells.
• The initial award, supported by grant number 1R01AI10266301, is for $531,600 for fiscal year 2012.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Antibody Protects Mice from Zika Infection
Researchers develop human-derived antibody protected pregnant mice and their developing fetuses from Zika infection.
Wednesday, November 23, 2016
NIH Researchers Unveil New Wound-Healing Role for Protein-Folding Gene in Mice
The study found that topical treatment of an Hsp60-containing gel dramatically accelerates wound closure in a diabetic mouse model.
Friday, October 28, 2016
Ebola-Affected Countries Receive NIH Support
The National Institutes of Health has established a new program to further research capacity to study Ebola and other epidemics.
Thursday, October 27, 2016
Skin Patch to Treat Peanut Allergy
NIH-funded study suggests peanut protein patch is a safe and convenient method of treatment.
Thursday, October 27, 2016
Sustained SIV Remission Achieved in Monkeys
Experimental treatment boosts monkey immune system to force SIV into sustained remission.
Wednesday, October 26, 2016
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Thursday, October 20, 2016
DNA Vaccines Protect Monkeys Against Zika Virus
Two experimental Zika virus DNA vaccines developed by NIH scientists protected monkeys against Zika infection.
Wednesday, October 05, 2016
Researchers Find a Gap in the Brain’s Firewall Against Parkinson’s Disease
Researchers at NIH have found mouse study that identified a key player in the progression of the disorder.
Saturday, October 01, 2016
Oxygen Can Impair Cancer Immunotherapy
Researchers have identified a mechanism within the lungs where anticancer immune resposnse is inhibited.
Friday, August 26, 2016
New Inflammatory Disease Discovered
NIH researchers have discovered a rare and potentially deadly disease - otulipenia - the mostly affects children.
Tuesday, August 23, 2016
Oral Immunotherapy Is Safe, Effective Treatment for Peanut-Allergic Preschoolers
Study demonstrates the potential of peanut OIT to suppress allergic immune responses to peanut.
Friday, August 12, 2016
Mutations Linked to Immunotherapy Resistance
Researchers uncover mutations in tumors of three patients with advanced melanoma that allowed the tumors to become resistant to the immune checkpoint inhibitor pembrolizumab (Keytruda®).
Tuesday, August 09, 2016
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
Friday, July 29, 2016
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Wednesday, July 27, 2016
NIH Investment Into HIV Research Expands
Funding has been awarded to six research teams to lead collaborative investigations worldwide toward an HIV cure.
Thursday, July 14, 2016
Scientific News
New Regulator of Immune Reaction Discovered
Calcium signal in cell nucleus regulates not only many brain functions but also defence reactions of the immune system.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Cell’s ‘Built-In Circuit’ Help Prevent Tumour Growth
Researchers have created cells with a 'built-in genetic circuit' that inhibits tumour growth.
Factors Behind Suppression of Stem Cell Mobilization Revealed
The findings could lead to improvements in transplantation therapy.
Common Virus Helps Fight Liver Cancer
Reovirus, a cause of childhood colds, stimulates the immune system to kill cancerous cells.
Antibody Protects Mice from Zika Infection
Researchers develop human-derived antibody protected pregnant mice and their developing fetuses from Zika infection.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
T Cell Channel Could Be Targeted to Treat Cancers
Researcher identify ion-channel found within T cells that could be targeted to reduce development of neck and head cancers.
Targeting Pancreatic Cancer
Cutting-edge technology exploits cancer cells’ vulnerabilities to develop new treatments.
A Genome-wide View of Human DNA Viruses
In this study, Duplex sequencing was used to accurately analyse the genome-wide rate of spontaneous mutation of human adenovirus C5 (HAdv5).
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!